Introduction
============

Nuclear receptors are transcription factors that play a key role in both embryonic development ([@bib3]) and adult homeostasis ([@bib27], [@bib4], [@bib23]), and are a common target for drug developers treating human diseases such as cardiovascular, cancer, and autoimmune disorders ([@bib8]). Drugs in the market that modulate the activity of nuclear receptors represent over \$30 billion in pharmaceutical sales ([@bib16], [@bib28]). Such drugs include prednisolone and dexamethasone for modulating glucocorticoid receptors (GRs), diethylstilbestrol and 4-hydroxytamoxifen for modulating estrogen receptors (ERs), and spironolactone (Aldactone) and eplerenone (Inspra) for modulating mineralocorticoid receptors ([@bib16]). Interestingly, drugs that modulate the control of the same nuclear receptors are used to treat a diverse set of diseases, an effect that is attributed to the role of nuclear receptors in regulating many distinct intracellular pathways at the gene transcription level ([@bib16]).

ERs are members of the nuclear receptor steroid family and have long been targets for therapeutic development, including the selective ER modulators (SERMs). The most prominent and best understood forms of the estrogen receptor are ER-α and ER-β, which share significant sequence homology ([@bib1]), but display tissue-specific gene expression patterns ([@bib6]), which can determine their use as effective therapeutic targets. In the case where ER-α and ER-β are coexpressed in the same tissues, they can form active homo- or heterodimers upon binding ER ligands ([@bib8]). While several ER isoforms, such as ER-β2, ER-β3, ER-β4, and ER-β5 are known to exist, the biological significance of isoforms remains to be determined, although they may dimerize with ERs and enhance ER transactivation in a ligand-dependent manner ([@bib18]). Estrogens and SERMs are known to bind and activate both ER-α and ER-β, making them useful for treating diseases, such as breast cancer, osteoporosis, and menopausal symptoms ([@bib16]).

Binding of structurally dissimilar ER ligands can affect ER conformation along with the composition of the ER transcription complexes ([@bib2]). These phenomena may depend on the size and shape of the ligand-binding domains (LBDs), which vary between subtypes. The LBD for ER-α is substantially larger than for ER-β, 450 vs 390 Å^3^ respectively ([@bib24]). This difference likely impacts the ER ligand-binding affinity, orientation of the ER ligand in the ligand-binding pocket, conformation of the ligand-bound ER, ER dimerization, coactivator and corepressor binding, and function of the receptors in their transcription complexes ([@bib24]). Helix 12 of both ER-α and ER-β has been shown to be essential for transactivation of gene expression, as loss of function mutations within this region results in a nonfunctional receptor even in the presence of ligand ([@bib7]). Notably, the position of helix 12 in the ERs is thought to be dependent on the particular bound ER ligand, and the helix 12 position affects the receptor function. For example, when 17β-estradiol (E~2~) is bound within the ligand-binding pocket of ER-α, helix 12 is oriented over the ligand-binding cavity and is packed against helixes 3, 5/6, and 11 in an agonist conformation ([@bib2]). By contrast, the binding of raloxifene within the ligand-binding pocket orients helix 12 to lie in a groove formed by helix 5 and the carboxy-terminal end of helix 3 in an antagonist conformation ([@bib2]).

Binding of different ligands to nuclear receptors, such as the ERs, can alter their conformation ([@bib2], [@bib25], [@bib5], [@bib16]) resulting in ligand-dependent gene transcription profiles ([@bib10], [@bib17]). Studies with ER ligands have confirmed that slight changes in stereochemistry or modifications to small substituents can alter subtype selectivity and shift receptor-binding potency by orders of magnitude ([@bib11]). Accordingly, a plethora of ER ligands have been synthesized that are built around a diversity of core structures including polycyclic cores, acyclic cores, macrocyclic cores, and heterocyclic cores ([@bib11]). However, analogs designed for specificity to a particular ER subtype have not always aligned with the desired biological activity.

In this study, we used gene expression data obtained from three different human tumor cell lines as a predictor of biological function for closely related E~2~ analogs that were designed in-house. We employed ER-binding and functional assays to further examine the attributes of each ligand, along with cell-based assays to confirm the effect that specific ligand structures impart on the fate of cells. Beginning with the core E~2~ structure, analogs were devised with new substituents at the C-6 of ring B or the C-18 of ring D. For the three E~2~ analogs studied here, we show that subtle structural changes in the core E~2~ can affect both ER selectivity and gene expression pathways responsible for cell growth and differentiation. The potential of the three E~2~ analogs studied here for treating human diseases, such as multiple sclerosis and cancer, supports the viability of this approach for drug discovery.

Materials and methods
=====================

Chemical synthesis
------------------

Details for synthesis of the E~2~ analogs ([Fig. 1](#fig1){ref-type="fig"}) are found in [Supplementary Figure 1](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1)A, B and C, see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article. Briefly, NDC-1022 was prepared starting from E~2~ ([Supplementary Figure 1](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1)A) and was obtained as a white solid with a purity of 98%. As the starting material was E~2~, care was taken in column chromatography to ensure that \<10 ppm E~2~ was present in the final material used in the assays for these studies. The chiral purity of the 17β-isomer was at least 95%. The compound was kept stored at under −18 °C. NDC-1308 was prepared according to the scheme in [Supplementary Figure 1](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1)B. Starting from E~2~, NDC-1308 was obtained as a solid, white foam with a purity of 95% and a chiral purity of 96%. Since the starting material was E~2~, care was taken in column chromatography to ensure that \<10 ppm E~2~ was present in the final material. The compound was kept stored at under −18 °C. NDC-1352 was prepared starting from NDC-1022 according to the scheme in [Supplementary Figure 1](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1)C. NDC-1352 was obtained as a white solid with a purity of 95% starting with NDC-1022. The compound was kept stored at under −18 °C.

For the biological assays, E~2~ and the E~2~ analogs were first dissolved in DMSO to a stock concentration of 10--100 mM and then serially diluted to the appropriate concentrations.

Cell lines
----------

Cell lines used for the cytotoxicity assay include NIH-H23, CAPAN-1, CAPAN-2, MDA-MB-231, MCF-7, and OVCAR-3 obtained from ATCC (Manassas, VA, USA) or SK-OV-3, A-549 obtained from the NCBI (Bethesda, MD, USA). Cell lines were grown in RPMI (SK-OV-3, NCI-H23, MDA-MB231, A-549, MCF-7), RPMI with 10 mM HEPES/20%FBS (OVCAR-3), Iscove\'s Modified Dulbecco\'s Media (CAPAN-2), or McCoy\'s 5a Modified Media (CAPAN-1).

Molecular modeling
------------------

Modeling studies were performed with ICM-Pro v.3.6-1e licensed from Molsoft, LLC (San Diego, CA, USA). The coordinates for ER-α and ER-β in various conformations were obtained from the Protein Data Bank (PDB, [www.rcsb.org](http://www.rcsb.org)). The evaluation of several different coordinate files allowed us to explore protein flexibility. Generation of protein--ligand complexes, using different receptor conformations, was achieved using the Docking module in ICM-Pro. Evaluation of fitness of docks, and effects of the C-18 methyl group, was done by first generating docked complexes between the ligand of interest and ER-α (derived from PDB entry 1KQT) and ER-β (derived from PDB entry 2J7X). These docks were then energy minimized to convergence using the Molecular Mechanics function using the 'boundary element' with a dielectric constant=8 for the electrostatic term. In this minimization, the ligand and protein residues within 5 Å of the ligand were free to move while the rest of the protein was fixed. The energetics between the protein and the ligand of the minimized complex was then evaluated using the 'show energy' function using the 'vw, sf, el and en' terms.

ER-binding assays
-----------------

Recombinant ER-α and ER-β were supplied by PanVera (Madison, WI, USA). The ^3^H-E~2~ was obtained from New England Nuclear (Boston, MA, USA). The binding assay was carried out by incubating the recombinant ER-α or ER-β with appropriate amount of ^3^H-E~2~ in the presence or absence of various concentrations of test compounds at 4 °C overnight in 200 μl binding buffer with pH 7.4 (10 mM Tris--HCl, 10% glycerol, 1% albumin, 1 mM phenylmethylsulfonyl fluoride, 25 nM leupeptin). Various concentrations of nonlabeled E~2~ were tested in the same assay. Nonspecific binding was determined using a concentration of the nonradiolabeled E~2~ at 100 times that of the ^3^H-E~2~ in the same assay tube. At the end of incubation, the bound ^3^H-E~2~ was separated from the free unbounded ^3^H-E~2~ using 60% hydroxyapatite (HAP) in binding buffer. An aliquot of the supernatant was mixed with 4 ml ScintiSafe (Fisher Scientific, Hampton, NH, USA) and the radioactivity was measured on a scintillation counter. The relative binding affinity of the test article was the amount of nonradioactive E~2~ required to displace 50% of radioactive E~2~ bound to ER relative to the amount of nonradioactive test compound required to displace 50% of radioactive E~2~ bound to ER×100.

Receptor dimerization assays
----------------------------

Bioluminescent resonance energy transfer (BRET) assays were performed as previously described (Powell & Xu 2008). Briefly, HEK293 cells were transfected with pCMX-ERα-RLuc or pCMX-RLuc-ERβ BRET fusion constructs in combination with empty vector, pCMX-ERα-YFP and pCMX-YFP-ERβ. The following cotransfections were used to assess dimer formation: pCMX-ERα-RLuc/pCMX-ERα-YFP for ER-α homodimers, pCMX-ERα-RLuc/pCMX-YFP-ERβ for heterodimers, and pCMX-RLuc-ERβ/pCMX-YFP-ERβ for ER-β homodimers. Twenty-four hours after transfection, ∼50 000 cells/well suspended in PBS were seeded in triplicate onto a white 96-well plate and treated with the corresponding compounds or vehicle (0.6% DMSO). After an 1 h incubation with ligand, coelenterazine h (Promega) was added to a final concentration of 5 μM, and emission at 460 and 530 nm was detected using a Victor X5 microplate reader. BRET ratios were calculated as described previously ([@bib22]), and the ratios represent the energy transfer between the donor and acceptor molecules. Higher BRET ratios are indicative of dimerization.

Gene transcription assays
-------------------------

The plasmids for ER-binding element luciferase reporter (pERE) and for ER-β cDNA expression vector (pER-β) were supplied by Addgene (Cambridge, MA, USA). The plasmid for the ER-α cDNA expression vector (pER-α) was obtained from OriGene Technologies, Inc. (Rockville, MD, USA). The Dual-Luciferase kit for measuring luminescence was obtained from Promega. MDA-MB-231 cells were seeded in 12-well plates at a density of 1.5×10^5^ cells/well in medium without antibiotics. Cells were allowed to grow overnight to 50--70% confluence before transfection. For transfection, an appropriate amount of pERE, pER-α or pER-β reporter plasmid and internal control plasmid pRL-TK was cotransfected transiently into cells. Transfection was performed using TurboFectin8 (OriGene) according to the protocol provided by the supplier. Cells were then treated with either E~2~ or the E~2~ analogs. After incubating for 24 h at 37 °C, cells were washed once with PBS, and then lysed with buffer provided by the supplier. The ratio of firefly compared with renilla luminescence was calculated for each treatment group. The functional expression of each compound was expressed as a percentage of the E~2~ ratio (100%) measured at 10 nM.

DNA microarray
--------------

Three human tumor cell lines, A-549, Panc-1, and SK-OV-3, were selected based on their endogenous levels of ER-α and ER-β and each grown in two flasks cultured to roughly 50% confluence. Cells were treated for 24 h with either the E~2~ analogs or 10% DMSO at concentrations of compound specified in [Table 1](#tbl1){ref-type="table"}. At termination, the cells were scraped free and washed in ice-cold PBS, collected by centrifugation, and immediately frozen at −80 °C. Total RNA was prepared from the frozen tissue samples using Trizol-based cell lysis followed by 65 °C hot phenol extraction and RNeasy chromatography purification (Qiagen). The concentration of RNA was determined by measuring the absorbance at 260 nm (A260). RNA purity was assessed by confirming that extracted RNAs had an A260/A280 ratio of 1.8 or greater. The RNA was then tested for relative integrity by determining the ratio of intact 28S and 18S rRNAs by capillary electrophoresis with the Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). All RNAs accepted for array analysis had ratios exceeding 1.0.

RNAs were labeled using 1 μg RNA as input to Low Input labeling reaction (Agilent Technologies) with Cy5 (650 nm emitter) and reference RNA was labeled with Cy3 (550 nm emitter) nucleotides. Labeling, hybridizations, and subsequent washings were carried out on with the Human GE 4x44K v2 G4110B (NDC-1308, NDC-1022) or the Human GE 4x44K v2 G4845A (NDC-1352) microarray kits from Agilent Technologies, according to the manufacturer\'s instructions. The resulting hybridized chips were scanned (G2505 Scanner, Agilent Technologies), and the intensity information for each detector spot was extracted from the scanned image using Agilent feature extraction software version 10.5.1.1. The filtered raw data for each microarray spot can be accessed in [Supplementary Table 1](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article. For analysis, a threshold of *P*≤0.001 was used as the cutoff point for significant change in mRNA abundance between the compound-treated and vehicle-treated samples.

Cytotoxicity assays
-------------------

NDC-1022, NDC-1308, NDC-1352, E~2~ (Sigma), and tamoxifen (Sigma) were each dissolved in DMSO at 100 mM. For dilutions, the 100 mM DMSO stock was added to the appropriate media and serially diluted in the same media such that the final DMSO contribution was ≤1% (v/v).

Each cell line was maintained at 5% CO~2~, 37 °C, and 95% relative humidity in the appropriate media including all necessary supplements. The cells were subcultured every 2--3 days and plated in tissue culture-treated, white/clear-bottom 96-well plates and incubated at 5% CO~2~ and 37 °C overnight before initiation of the assay. The media in the cell plate (100 μl) was replaced with fresh media (100 μl) immediately before adding the 100 μl test articles; the media were not estrogen-depleted. Wells containing no cells were used for background controls. Tamoxifen was used as a known positive control for each assay and DMSO was included as the vehicle control. The cells were incubated at ∼37 °C in humidified 5% CO~2~ atmosphere for 72 h.

Cell number was determined by measuring the ATP levels using the CellTiter-Glo Kit (Promega). Luminescence was measured with the Infinite M200 plate reader (Tecan, Durham, NC, USA). The mean baseline controls (wells with no cells) were subtracted from the total luminescence to determine the net luminescence for that well. This total was compared with the vehicle control of DMSO only. Both EC~50~ and EC~90~ values were calculated using Sigma Plot 11.0 (Systat Software, Inc., San Jose, CA, USA). The lower EC~90/50~ values help to identify cell lines that are more susceptible to compounds.

Oligodendrocyte differentiation assays
--------------------------------------

Oligodendrocyte precursor cell (OPC) cultures were prepared as previously described ([@bib19]). Briefly, brains were removed from E14.5 C57Bl6/J (expressing PLP-EGFP) mice ([@bib14]), cleaned, and cortical hemispheres were isolated. Tissue was then triturated and seeded into T-25 cm^2^ flasks at a density of one brain (two cortical hemispheres) per flask. Neurospheres were passed once after 3 days. Cells from passage two were used to prepare two 96-well plates for the primary screen. Following the initial 48 h incubation in OPC media, the OPCs were treated with 10 μM of E~2~, NDC-1022, NDC-1308, and NDC-1352 along with vehicle control DMSO and positive control compounds including 20 ng/ml ciliary neurotrophic factor (CNTF) and 1 μM ERK kinase inhibitor (MEKi). Cells were treated for a total of 4 days and the media was replaced once at the 48 h mark with fresh compounds. After the 4 day treatment, the cells were fixed with 4% paraformaldehyde and stained with Hoechst 33342 to visualize nuclei. Cells were also stained with anti-GFAP antibodies to identify astrocytes. Briefly, cells were blocked with 3% normal goat serum followed by an overnight incubation of anti-rabbit GFAP antibody (1:500). Cells were labeled with a 1:1000 concentration of secondary goat anti-rabbit Alexa 647 fluorochrome antibody. Images were acquired using the Cellomics Arrayscan VTI. Twenty fields at 10× magnification were acquired per well and the cells expressing EGFP (mature oligodendrocytes) and GFAP (astrocytes) were evaluated by neuronal profiling algorithm.

Statistical analysis
--------------------

For the BRET assays, the values for each compound were compared with DMSO control for each dimer condition using a one-tailed Student\'s *t*-test with significant difference *P*\<0.05. For the DNA microarray studies, significant (*P*\<0.001) up- or downregulated genes were identified by comparing the E~2~ analog-treated and vehicle-treated samples from each tumor cell line. Genes were included in the relevant signaling pathways ([Table 1](#tbl1){ref-type="table"}) only if they were consistently regulated in the same manner for all three tumor cell lines. For the oligodendrocyte differentiation studies, ANOVA showed statistically significant differences (*P*\<0.001) between the different treatment groups. Comparisons of E~2~ analogs, MEKi, and CNTF were then made to control DMSO using a Student\'s *t*-test with significant difference *P*\<0.001.

Results
=======

Molecular modeling of E~2~ analogs in the ER LBD
------------------------------------------------

The structures of E~2~ and the synthesized E~2~ analogs are shown in [Fig. 1](#fig1){ref-type="fig"}. Alkoxyalkyl substituents were added to the C-6 position of the E~2~ B-ring for all three analogs while the C-18 methyl was removed to create NDC-1352 ([Supplementary Figure 1](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1)A, B and C).

Docking studies of these compounds to various receptor conformations, allowing for the exploration of protein flexibility of both ER-α and ER-β, were carried out using the docking algorithm implemented in ICMpro and generated two possible docking poses. Using NDC-1022 as an example, in one pose ([Fig. 2A](#fig2){ref-type="fig"} and B) the steroid core would bind in the same manner that E~2~ does (E~2~-like). In the second pose ([Fig. 2C](#fig2){ref-type="fig"}) the E~2~ analogs bind in an 'upside down' manner similar to the way both 16-α, E~2~ (DOI: 10.2210/pdb2j7y/pdb) ([@bib21]) and ICI 164 384 (DOI: 10.2210/pdb1hj1/pdb) bind. These two different binding modes represent isomeric complexes of a single compound, differing in both the relative position of the ligand in the binding site and the conformation of the protein. It should be noted that for ER-β, the binding affinity decreases with ligand volume, whereas for ER-α, binding affinity increases with ligand volume, which is consistent with this model.

We propose the E~2~-like docking pose as the most likely pose for the E~2~ analogs studied here. In the E~2~-like orientation for NDC-1308 ([Fig. 2D](#fig2){ref-type="fig"}), the C-6 alkoxyalkyl groups of the E~2~ analogs could fold on top of the steroid core of the ligand, binding to a pocket of the ERs that E~2~ would not be able to interact. The C-6 groups in this orientation could fit into a small hydrophobic pocket formed by the side chain of Met-291, Leu-294, and Met-295 of ER-β (corresponding to Leu-384, Leu-387, and Met-388 of ER-α) although this appears to be a rather crowded fit. We predict that this crowded fit results in subtle conformational changes in the ER leading to altered transcriptional activities.

In the E~2~-like bound orientation of NDC-1022, the C-6 side chain could make van der Waals interactions with the C-18 methyl. In NDC-1352, the C-18 methyl is absent. To simplify the modeling analysis, the effect of the C-18 methyl was examined by comparing the binding of E~2~ with nor-C-18-methyl-E~2~ (norMe_E~2~). For ER-β, norMe_E~2~ had slightly more favorable van der Waals interactions than did E~2~. For ER-α, the situation was reversed in that norMe_E~2~ had slightly less favorable van der Waals interactions than did E~2~. It should be noted that for ER-α, the C-18 methyl group of E~2~ makes van der Waals interactions with the side chain of Leu-384, whereas with norMe_E~2~ with a hydrogen at this position, a small gap between ligand and protein is created. For ER-β, the C-18 methyl group of E~2~ interacts with the side chain Met-291. As the methionine side chain is somewhat flexible, it is better able to fill in the gap between the C-18 hydrogen in norMe_E~2~ and the ER-β protein. Similarly, the somewhat flexible nature of Met-291 in ER-β might allow for a better induced fit of the C-6 side chain of NDC-1352 within ER-β compared with the less flexible Leu-384 of ER-α. Thus, the substitution of the C-18 methyl group of NDC-1022 for a hydrogen in NDC-1352 is expected to result in an increased β-selectivity of NDC-1352. The E~2~-like binding pose represents the agonist conformation of the ER and provides a better proposed fit for the E~2~ analogs compared with the 'upside down' binding pose ([Fig. 2C](#fig2){ref-type="fig"}).

Binding of the E~2~ analogs to ERs
----------------------------------

Each E~2~ analog along with reference E~2~ was assessed for binding affinity to ER-α and ER-β using *in vitro* recombinant receptor binding assays. The analogs were found to possess distinctly different binding affinities for ER-α and ER-β ([Table 2](#tbl2){ref-type="table"}). Although it has a large alkoxyalkyl moiety at C-6, the 1/β:α ratio for NDC-1308 shows that there is no significant preference for binding either ER-α (IC~50~ 70 nM) or ER-β (IC~50~ 100 nM), similar to E~2~. On the other hand, NDC-1022 and NDC-1352 each have a smaller alkoxyalkyl moiety at C-6 and are structurally more similar to E~2~ than NDC-1308, yet both preferentially bind ER-β over ER-α. NDC-1022 had a greater than sixfold higher binding affinity to ER-β than ER-α, while NDC-1352 had a \>100-fold higher affinity to ER-β. The different ER-β/ER-α binding ratios for NDC-1022 compared with NDC-1352 demonstrate the impact that a seemingly innocuous hydrogen substitution (NDC-1352) for a methyl group (NDC-1022) at C-18 can make on receptor binding in combination with an alkoxyalkyl moiety at C-6.

While some ligands have been found to cross-react with different classes of hormone receptors ([@bib12]), there was no significant binding of either NDC-1308 or NDC-1022 to the androgen (AR), progesterone (PR), or GR receptors. The IC~50s~ for DHT (AR control), progesterone (PR control), and dexamethasone (GR control) were 8.5, 1.3, and 6.6 nM respectively. By contrast, the IC~50~ of NDC-1022 was \>3000 nM for all three receptors, while the IC~50~ of NDC-1308 was \>3000 nM for AR and GR and 1200 nM for PR. NDC-1352 was not evaluated in this assay.

Dimerization of ERs following E~2~ analog binding
-------------------------------------------------

The binding of exogenous ligands to ER-α and ER-β and subsequent dimer formation is an initial step required for transcriptional activation. In cells expressing both ER-α and ER-β, homo- and heterodimers can readily form following the binding of estrogens ([@bib8]). NDC-1022 and NDC-1308 were tested for their ability to cause homo- and heterodimer formation *in vitro* using a BRET assay that measures the ERα/β heterodimerization in a cell-based physiological environment in real time ([@bib20], [@bib22]). Although NDC-1022 caused all combinations of homo- and heterodimers to form at concentrations of 1 μM or greater, α/β heterodimers and β/β homodimers were preferred at 100 nM ([Fig. 3A](#fig3){ref-type="fig"}). By contrast, NDC-1308 induces all dimer formations starting at 1 μM but with no preference for either form ([Fig. 3B](#fig3){ref-type="fig"}). BRET assays for ER-β homodimerization typically show 1.5- to 2-fold inductions with E~2~ treatment because of high ligand-independent dimerization, which has been previously described by [@bib22]. In addition, conformational changes within the receptor fusion proteins allow for efficient energy transfer, and the BRET ratios are dependent on the conformational changes induced by different ligands, thereby affecting the BRET ratio output. Although NDC-1022 and NDC-1308 do not induce BRET ratios to the same extent as E~2~, there is significant ER dimerization induced by both compounds. Since ERs are transcription factors, the ability of these E~2~ analogs to form ER dimers *in vitro* suggested that they would drive gene expression in cells.

Activation of ERs by E~2~ analogs
---------------------------------

Compounds NDC-1022, NDC-1308, and NDC-1352 were assayed for transcriptional activity from both ER subtypes, and compared to E~2~ for reference. Reporter gene transfection assays were conducted in MDA-MB-231 cells using expression plasmids for either full-length ER-α or ER-β and an estrogen-responsive luciferase reporter gene system.

Overall, the E~2~ analogs were more potent agonists of ER-β than ER-α (refer to β:α functional selectivity in [Table 2](#tbl2){ref-type="table"}), but less potent ER activators compared with E~2~. Functional selectivity was dose-dependent for NDC-1022 and NDC-1308 as both favored ER-β over ER-α at 10 and 100 nM. The selectivity was not observed at, or above, 1 μM of ligand ([Table 2](#tbl2){ref-type="table"}). Treatment of cells with NDC-1352 caused 15- to 20-fold more transcription from the reporter gene for ER-β than ER-α, even up to the highest concentration of ligand tested (10 μM, data not shown), which is consistent with the results from the binding affinity assay.

In a separate follow-up study, the addition of an ER antagonist, ICI 182 780 (100 nM), to the culture media of the cells for the luciferase assay effectively competed away the transcriptional activity of the reporter gene by NDC-1022 and NDC-1308 at all concentrations, for both ER-α and ER-β ([Supplementary Figure 2](http://jme.endocrinology-journals.org/cgi/content/full/JME-12-0083/DC1), see section on [supplementary data](#supp1){ref-type="sec"} given at the end of this article). This demonstrates that the E~2~ analogs are indeed functioning through the ERs.

E~2~ analog-dependent intracellular signaling
---------------------------------------------

As the gene activity measured by the luciferase functional assays are associated with only one estrogen response element (ERE) and nuclear receptors influence many genes and pathways from various EREs, the global transcriptional effect of the E~2~ analogs was assessed by DNA microarray. Gene expression profiles were determined by microarray in three different human tumor cell lines, which vary in their endogenous amounts of ER-α and ER-β. A-549 is an ER-α negative, ER-β positive human lung adenocarcinoma cell line ([@bib9]). Panc-1 is an ER-α positive, ER-β positive pancreatic tumor cell line ([@bib15]). SK-OV-3 is an ER-α positive, ER-β positive ovarian tumor cell line; however, there is a 32-bp deletion in ER-α rendering it nonfunctional ([@bib13]). Cells were treated with varying amounts of each E~2~ analog at concentrations ranging from 10 to 100 μM in order to ensure complete dimer formation ([Fig. 3](#fig3){ref-type="fig"}) and full activation of the ERs ([Table 2](#tbl2){ref-type="table"}).

[Table 1](#tbl1){ref-type="table"} summarizes the microarray dataset for differentially expressed genes found in key signaling pathways. Each gene listed in [Table 1](#tbl1){ref-type="table"} was selected due to its common change in expression across all three tumor cell lines following treatment with each compound. The values in the table represent the mean expression (log2) across all three cell lines. For NDC-1022 and NDC-1308, all three cell lines showed on average a i) 2- to 75-fold upregulation of genes in signaling pathways related to OPC differentiation, ii) one- to fivefold downregulation of genes for signaling pathways related to chromosome replication, and iii) 1- to 25-fold upregulation of genes in signaling pathways controlling cell death. For both analogs, the response of the cells at the transcriptional level was dose-dependent, yet the potency of NDC-1308 was significantly greater than NDC-1022. This is best demonstrated by comparing the magnitude of gene expression changes measured at 10 μM for NDC-1308 to 100 μM for NDC-1022 ([Table 1](#tbl1){ref-type="table"}). By contrast, genes within these signaling pathways were relatively unaffected by even the highest concentration of NDC-1352 (100 μM). Instead, with NDC-1352, chemokine genes possibly related to the immune system pathways or the pro-inflammatory pathways were upregulated (3- to 200-fold). As expected, housekeeping genes were not significantly up-regulated or uniformly downregulated by the E~2~ analogs.

As the changes in gene expression lead to distinct signaling pathways for each E~2~ analog, we reasoned that the pathway information derived from the tumor cell lines could be used to further distinguish the similar E~2~ analogs from each other in cell-based assays for viability (tumor cell death) and differentiation (neuronal precursor assays).

E~2~ analog-mediated tumor cell death
-------------------------------------

The gene expression profiles ([Table 1](#tbl1){ref-type="table"}) predict that NDC-1308 would be the most potent of the E~2~ analogs for inducing cell death. To test this, ten different human tumor cell lines obtained from six different tissue types were treated separately, with each of the three E~2~ analogs compared with tamoxifen and E~2~ as a reference ([Table 3](#tbl3){ref-type="table"}). On average, NDC-1308 (EC~50~ 18.0±2.2) was the most potent of the E~2~ analogs followed by NDC-1022 (EC~50~ 57.1±5.5) and NDC-1352 (EC~50~ 117.1±11.5). Treating cancer cells with NDC-1308 showed a dose-dependent ability to kill tumor cell lines with an EC~50~ ranging from 7 to 31 μM, which is similar to the potency of tamoxifen and about twofold more potent than E~2~ (18--52 μM). NDC-1022 also possessed a dose-dependent cytotoxic activity with an EC~50~ ranging from 33 to 85 μM, but as predicted from the microarray data ([Table 3](#tbl3){ref-type="table"}), was about threefold less potent than NDC-1308. Consistent with the microarray data, the potency of NDC-1352 (EC~50~ 50--150 μM) was about twofold less than NDC-1022, although the chemical structures are very similar ([Fig. 1](#fig1){ref-type="fig"}). The EC~90~ value was on average two- to tenfold lower for NDC-1308 compared with either E~2~ or the other E~2~ analogs, confirming that the structural changes made in the E~2~ core affect cell viability.

To test whether the E~2~ analogs directly induce cell death via the ERs, we used NDC-1352 as a competitive inhibitor for blocking the tumor cell death mediated by NDC-1308. We chose NDC-1352 because it binds almost exclusively to ER-β ([Table 2](#tbl2){ref-type="table"}), but is five- to tenfold less potent than NDC-1308 in the tumor cell viability assays ([Table 3](#tbl3){ref-type="table"}). To simplify the potential intracellular interactions of having both ERs present, we used the A549 tumor cell line as it endogenously expresses only a functional ER-β. We found that addition of 5 μM NDC-1352 significantly raised the IC~50~ (1.4-fold) and IC~90~ (1.9-fold) of NDC-1308. This means that tumor cell death induced by NDC-1308 is mediated through ER-β.

E~2~ analog-mediated differentiation of neuronal precursor cells
----------------------------------------------------------------

The gene expression data ([Table 1](#tbl1){ref-type="table"}) show that NDC-1022 and NDC-1308 upregulate genes in signaling pathways involved in myelin production and the differentiation of OPCs. To directly test for this activity, mouse OPCs were treated for 96 h with 10 μM of either NDC-1022, NDC-1308, or NDC-1352 and the extent of oligodendrocyte maturation measured by the level of the PLP-EGFP reporter signal ([Fig. 4](#fig4){ref-type="fig"}). Proteolipid protein (PLP) was used as a biomarker, because it is known to be expressed in mature oligodendrocytes and is a component of the myelin sheath. As shown in [Fig. 4A](#fig4){ref-type="fig"}, NDC-1308 was the most potent E~2~ analog having threefold more activity to differentiate OPCs compared with DMSO and 1.5- to 2.0-fold more activity than the positive controls, CNTF ([@bib26]) and MEKi ([@bib29]) respectively. The number of pyknotic nuclei for the E~2~ analog-treated cells (∼20% of total) was the same as the control DMSO- and CNTF-treated cells, indicating that the OPCs were not adversely affected by the drug treatment. As predicted from the microarray data, NDC-1352 did not cause significant OPC differentiation at 10 μM.

Discussion
==========

Previous reports have described a number of diverse ER ligands without adequately assigning a biological function to different substituents present in the chemical structures ([@bib10], [@bib18]). Towards this end, we integrated gene expression data derived from human tumor cell lines along with receptor binding and cell-based functional assays to ascertain the effect that a change in ER ligand structure imparts on ER function. The three E~2~ analogs studied here were designed with different substituents added or removed from the E~2~ core. While all three analogs are ER-β agonists, the structural modifications present in each compound led to unique ER dimerization, different subtype selectivity, and receptor-binding affinities, along with differential effects on gene expression, cell growth, and cell differentiation.

Structure--function relationships with modifications at the C-6 position (B-ring) of the E~2~ core have not previously been reported. However, our ER modeling data ([Fig. 2](#fig2){ref-type="fig"}) suggested that an alkoxyalkyl group addition containing at least four carbons at the C-6 position would fold over the B-ring of the E~2~ core. This could still allow the analogs to bind in the E~2~ orientation, but perhaps bind more compactly in the LBD of the receptor compared with E~2~. This provided the rationale to synthesize NDC-1308 with a six carbon alkoxyalkyl group at the C-6 position of E~2~ ([Fig. 1](#fig1){ref-type="fig"}, B-ring). As a comparator, NDC-1022 was constructed with a single carbon alkoxyalkyl group added to the E~2~ core. An additional modification was made at the C-18 ([Fig. 1](#fig1){ref-type="fig"}, D-ring) of NDC-1022 by changing the methyl group to a hydrogen atom. The resulting ligand, NDC-1352, is predicted to be primarily oriented in the LBD by virtue of the C-3 and C-17 alcohol groups in the E~2~ core.

While we originally viewed some of the structural differences in the three E~2~ analogs to be relatively innocuous compared with E~2~ and also with each other, it was surprising that each compound had vastly different binding affinity and ER subtype selectivity. NDC-1308 lacked a preferential affinity for either ER-α or ER-β, while NDC-1022 preferentially bound ER-β (greater than fivefold). Remarkably, NDC-1352 bound almost exclusively to ER-β (\>100-fold). For NDC-1308, the impact of the longer alkoxyalkyl side chain (six carbons) fitting more compactly in the LBD may explain the loss of ER-β selectivity for this E~2~ ligand compared with the other two E~2~ analogs. The striking gain in ER-β selectivity for NDC-1352 and the different gene expression patterns compared with NDC-1022 are solely attributed to the hydrogen substitution for the methyl at C-18 of the D-ring. The competitive binding assays showed that E~2~ had at least tenfold better binding to ER-β and 35-fold better binding to ER-α than the best E~2~ analog, probably due to the overall bulkiness of the alkoxyalkyl side chains added to the C-6 position of each E~2~ analog.

Moreover, a plausible explanation for why NDC-1308 is more potent and less selective than NDC-1022 is because the longer side chain of NDC-1308 makes additional van der Waals interactions to stabilize it within the ligand-binding cleft of both receptors. The enhanced ER-β selectivity of NDC-1022 may be due to the C-6 side chain making van der Waals contacts with residues that are different between ER-α (Leu-384) and ER-β (Met-291). Likewise, the remarkable ER-β selectivity of NDC-1352 may be explained by the loss of the C-18 methyl from the core structure and the interaction it normally makes with these same residues.

ERs bind ligand and dimerize to become part of an active transcription complex. We evaluated the potential of NDC-1022 and NDC-1308 to form ER-α and ER-β homo- and heterodimers *in vitro* as a predictor of their ability to activate and regulate transcription in cell lines. Compounds NDC-1022 and NDC-1308 act similar to other estrogens by causing the formation of ER homo- and heterodimers ([@bib8]). The results of the dimer formation assays showed NDC-1308 to be more promiscuous than NDC-1022 for ERs, consistent with the receptor binding data. That the E~2~ analogs could specifically activate transcription via ERs was confirmed by functional assays showing that each functions as ER agonists, with no detectable cross-reactivity for the ARs, PRs, and GRs.

Based on their different ER subtype selectivity and knowing that ER activation is not an 'on-off' switch, we anticipated that the E~2~ analogs would elicit different cellular responses. We used microarray data from human tumor cell lines to distinguish the structure of each ligand for key intracellular signaling pathways and ultimately to predict biological responses. Choosing tumor cell lines derived from diverse tissues (lung, pancreas, and ovary) ensured that common signaling pathways would be detected independent of genetic background or levels of ER expression. This strategy also filters away significant gene expression changes that are due to cell line-specific coactivators and corepressors. In addition, the human tumor cell lines were treated with micromolar concentrations of each E~2~ analog to ensure full dimerization ([Fig. 3](#fig3){ref-type="fig"}) and activation ([Table 2](#tbl2){ref-type="table"}) of the ERs within the 24 h incubation period. We were able to identify common signaling pathways in all three human tumor cell lines for each E~2~ analog.

Identifying the dramatic regulation of key genes within several specific signaling pathways helped us predict the biological response for each E~2~ analogs. For example, the dramatic upregulation of *MBP*, *OLIG2*, and *MOG* at the lowest dose of NDC-1308 (10 μM) predicted an activity for differentiation of OPCs. This was confirmed *in vitro* using a mouse OPC differentiation assay ([Fig. 4](#fig4){ref-type="fig"}) where NDC-1308 had the most potent activity (EC~50~ 1.0 μM, data not shown). Conversely, at higher concentrations both NDC-1308 (50 μM) and NDC-1022 (100 μM) caused dramatic downregulation of *MCM4*, *MCM10*, *GTSE1*, *SPC25*, and other genes essential for chromosome replication. Moreover, NDC-1308 and NDC-1022 cause a substantial upregulation of genes for cell death including *GDF15*, *GZMK*, and *GADD45A*. This predicted cytotoxic activity at higher concentrations of the E~2~ analogs, which was confirmed in the cell-based viability assay for both NDC-1308 and NDC-1022 ([Table 3](#tbl3){ref-type="table"}). That NDC-1352 is less cytotoxic and does not cause OPC differentiation is consistent with the gene expression data, and points out the dramatic effect that a hydrogen substitution for a methyl group can make at C-18 of the core E~2~. NDC-1352 does elicit a dramatic upregulation of chemokine, metallopeptidases, and a complement component suggesting a potential role in stimulating inflammation. Notably, this specific transcriptional upregulation is absent in NDC-1308 and NDC-1022.

As described above, the altered transcriptional activities of these E~2~ analogs could be attributed to conformational changes in the ER resulting from adding the different C-6 alkoxyalkyl side chains. Likewise, removing the C-18 methyl group of the E~2~ core affected ER activation. Except for a hydrogen atom substituted in place of a methyl at C-18, NDC-1352 is structurally identical to NDC-1022. The modeling data suggest that the absence of the C-18 methyl group of NDC-1352 allows for a better fit of the C-6 side chain in ER-β than in ER-α. This could explain why remarkably different gene expression differences were obtained in key signaling pathways for NDC-1352 compared with NDC-1022. Taken together, the comparison of gene expression and functional data for NDC-1352 and NDC-1022 demonstrates how a critical alteration in the core E~2~ structure can dramatically alter the cellular response.

Our data confirm and extend the notion that the inherent structure of specific ER ligands has a major impact on gene expression events that control cell fate. Structural modifications of E~2~ analogs at the C-6 and C-18 positions led to dramatic differences in the activation of the ERs that ultimately led to tumor cell death or neuronal cell differentiation. The use of ER competitors in transcriptional assays and the cell viability assay is consistent with the activity of the E~2~ analogs being directed through the ERs. Furthermore, the activities reported here only require the presence of functional ER-β as two (A-549 and SK-OV-3) of the three tumor cell lines used for the microarray study do not make a functional ER-α protein. These studies support the notion that by using this approach for drug discovery, ligands for nuclear receptors may be designed for treating a variety of diseases, such as multiple sclerosis and cancer.
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![Structures of the E~2~ analogs. The analogs differ from E~2~ and each other in either the length of the 6-alkoxyalkyl group at C-6 in the B ring or in the presence or absence of the C-18 methyl group in the D ring. The C-6 in the B ring and the C-18 in the D ring of E~2~ are denoted by arrows.](JME120083f01){#fig1}

![Docking analysis of E~2~ analogs into the ER-α and ER-β ligand-binding domains. (A) E~2~-like docking pose of NDC-1022 (green) to the ER-β agonist conformation (helix 12 purple). (B) There are subtle differences in the residues making contact with the ligand between ER-α (red residue labels) and ER-β (blue residue labels). See text for details. (C) Alternate 'upside-down' docking pose of NDC-1022 (green). (D) Ligand NDC-1308 (green) bound to ER-β (blue residue labels) in the E~2~-like orientation. Figures were created with ICMpro v3.7-2c.](JME120083f02){#fig2}

![BRET assays for determining ERα/β dimer formation by the E~2~ analogs. Shown is the level of α/α, α/β, or β/β dimer formation induced by (A) NDC-1022 and (B) NDC-1308. Data are representative of three independent experiments. Mean values are plotted with [s.d.]{.smallcaps}, *n*=3. \**P*\<0.05.](JME120083f03){#fig3}

![Differentiation of mouse primary OPCs with the E~2~ analogs. OPCs isolated from PLP-EGFP transgenic mice were treated with E~2~, the E~2~ analogs NDC-1022, NDC-1308 and NDC-1352 along with the positive controls CNTF and MEKi. After treatment, the cells were fixed and assayed for luminescence using the Cellomics Arrayscan VTI. Cells expressing EGFP (mature oligodendrocytes) were measured with a neuronal profiling algorithm. (A) Percent EGFP expressing cells (*y*-axis) after treatment with E~2~ and the E~2~ analogs are compared with negative (DMSO) and positive (CNTF, MEKi) controls. Mean values are plotted with [s.d.]{.smallcaps}, *n*=5. *P*\<0.001 to DMSO is denoted by '\*'. Representative images after treatment with DMSO (B), CNTF (C), and NDC-1308 (D). Visible are mature oligodendrocytes (green cells) and astrocytes (red cells) as well as Hoechst stained nuclei from undifferentiated OPCs (blue).](JME120083f04){#fig4}

###### 

Distinct gene expression patterns in human tumor cell lines induced by the E~2~ analogs

  **Gene name**                                                 **Symbol**   **Entrez gene GeneID**[c](#tblfn3){ref-type="table-fn"}   **Gene expression values**[**a,**](#tblfn1){ref-type="table-fn"}[**b**](#tblfn2){ref-type="table-fn"}                                   
  ------------------------------------------------------------- ------------ --------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------- ------- ------- ------- -------
  Oligodendrocyte progenitor cell differentiation                                                                                                                                                                                                                              
   Delta/notch-like EFG repeat containing                       DNER         92737                                                     5.16                                                                                                    5.51    6.20    4.79    0.00    0.00
   Oligodendrocyte lineage transcription factor 2               OLIG2        10215                                                     4.98                                                                                                    4.59    6.16    5.32    0.00    0.00
   Myelin basic protein                                         MBP          4155                                                      4.72                                                                                                    4.80    6.07    5.04    0.00    0.00
   Myelin oligodendrocyte glycoprotein                          MOG          4340                                                      3.99                                                                                                    4.28    5.23    5.55    0.00    0.00
   Interleukin 23 receptor                                      IL23R        149233                                                    3.62                                                                                                    4.86    5.31    5.46    0.00    0.00
   Transmembrane protein 108                                    TMEM108      66000                                                     3.59                                                                                                    3.62    3.92    3.96    0.00    0.00
   Connexin                                                     AF251047     100128922                                                 3.38                                                                                                    3.56    2.74    3.08    0.00    0.00
   Interleukin 20 receptor alpha                                IL20RA       53832                                                     3.17                                                                                                    3.38    4.42    4.39    0.00    0.00
   Interferon, lambda 2                                         IFNL2        282616                                                    1.35                                                                                                    1.96    1.44    2.59    −0.37   −0.37
  Chromosome replication                                                                                                                                                                                                                                                       
   Cell division cycle 25 homolog B                             CDC25B       994                                                       0.00                                                                                                    0.00    0.00    −0.71   0.00    0.00
   Minichromosome maintenance complex component 6               MCM6         4175                                                      0.00                                                                                                    −0.43   0.00    −1.76   0.00    0.00
   Flap structure-specific endonuclease 1                       FEN1         2237                                                      0.00                                                                                                    −0.52   −0.47   −1.76   0.00    0.00
   Minichromosome maintenance complex component 4               MCM4         4173                                                      0.00                                                                                                    −0.58   −0.29   −2.08   0.00    0.00
   Minichromosome maintenance complex component 10              MCM10        55388                                                     0.00                                                                                                    −0.68   −0.24   −2.17   0.00    0.00
   Origin recognition complex, subunit 1                        ORC1L        4998                                                      0.00                                                                                                    −0.74   −0.60   −1.68   0.43    0.27
   Aurora kinase A                                              AURKA        6790                                                      0.00                                                                                                    −0.73   −0.46   −1.44   0.00    0.00
   G-2 and S-phase expressed 1                                  GTSE1        51512                                                     0.00                                                                                                    −0.82   −0.53   −2.33   0.26    0.18
   Spindle pole body component 25 homolog                       SPC25        57405                                                     0.00                                                                                                    −0.82   −0.29   −2.28   0.00    0.00
   Minichromosome maintenance complex component 7               MCM7         4176                                                      0.00                                                                                                    −0.83   0.00    −0.99   0.00    0.00
   GINS complex subunit 1                                       GINS1        9837                                                      0.00                                                                                                    −0.93   −0.47   −1.94   0.00    0.00
   PIF1 5′-to-3′ DNA helicase homolog                           PIF1         80119                                                     0.00                                                                                                    −1.19   −0.50   −1.70   0.00    0.00
   Kinesin family member 20A                                    KIF20A       10112                                                     −0.38                                                                                                   −1.06   −0.38   −1.06   0.00    0.00
   Cell division cycle associated 8                             CDCA8        55143                                                     −0.25                                                                                                   −1.16   −0.22   −1.14   0.00    0.00
   Replication factor C (activator 1) 3, 38 kDa                 RFC3         5983                                                      −0.78                                                                                                   −0.97   −0.57   −1.84   0.40    0.34
  Cell death                                                                                                                                                                                                                                                                   
   Growth differentiation factor 15                             GDF15        9518                                                      1.26                                                                                                    2.50    1.36    3.47    0.49    0.81
   Calreticulin 3                                               CALR3        125972                                                    0.59                                                                                                    2.07    1.99    1.99    0.00    0.00
   Growth arrest and DNA-damage-inducible, alpha                GADD45A      1647                                                      0.00                                                                                                    0.00    0.32    4.60    0.00    0.00
   Granzyme K                                                   GzmK         3003                                                      0.00                                                                                                    0.00    3.94    3.73    0.00    0.00
   Apoptosis enhancing nuclease                                 AEN          64782                                                     0.00                                                                                                    0.00    0.36    1.13    0.00    0.00
  Immune system/inflammation                                                                                                                                                                                                                                                   
   Chemokine (C-C motif) ligand 11                              CCL11        6356                                                      0.00                                                                                                    0.00    0.00    0.00    8.66    8.39
   Complement component 6                                       C6           729                                                       0.00                                                                                                    0.00    0.00    0.00    8.20    7.47
   Chemokine (C-X-C motif) receptor 2, pseudogene 1             CXCR2P1      3580                                                      0.00                                                                                                    0.00    0.00    0.00    7.80    8.06
   ADAM metallopeptidase with thrombospondin type 1 motif, 8    ADAMTS8      11095                                                     0.00                                                                                                    0.00    0.00    0.00    4.42    4.03
   ADAM metallopeptidase with thrombospondin type 1 motif, 14   ADAMTS14     140766                                                    0.00                                                                                                    0.00    0.00    0.00    4.20    3.88
   Chemokine (C-C motif) ligand 22                              CCL22        6367                                                      0.00                                                                                                    0.00    0.00    0.00    3.82    3.49
   Chemokine (C-C motif) ligand 1                               CCL1         6346                                                      0.00                                                                                                    0.00    0.00    0.00    1.66    3.20
   Chemokine (C-C motif) ligand 8                               CCL8         6355                                                      0.00                                                                                                    0.00    0.00    0.00    1.66    3.20
  Housekeeping                                                                                                                                                                                                                                                                 
   Actin, alpha 2, smooth muscle, aorta                         ACTA2        59                                                        0.00                                                                                                    0.47    0.00    0.00    0.00    −0.24
   Ubiquitin B                                                  UBB          7314                                                      0.00                                                                                                    0.00    0.00    −0.48   0.00    −0.24
   Glyceraldehyde-3-phosphate dehydrogenase                     GAPDH        2597                                                      0.00                                                                                                    0.00    0.00    −0.20   0.00    0.00
   Actin, beta                                                  ACTB         60                                                        0.00                                                                                                    −0.29   0.00    −0.88   0.00    −0.59
   Ubiquitin D                                                  UBD          10537                                                     0.00                                                                                                    −1.09   −0.55   −0.68   0.00    0.00

All values are Log2 and represent the average of three independent microarray experiments.

Significant changes in gene expression, *P*\<0.0001.

Gene IDs conform to standards developed at the NCBI for the Entrez Gene database.

The E~2~ analogs have different potencies for inhibiting cell growth; gene expression was tested at the lowest concentration for the more potent NDC-1308.

###### 

Relative binding affinities and functional activation of E~2~ analogs to ERs and other hormone receptors

  **Ligand name**                             **Ligand binding affinity**[**b**](#tblfn6){ref-type="table-fn"} **IC**~**50**~ (nM)   **Functional selectivity**[**a**](#tblfn5){ref-type="table-fn"}                                                                                                 
  ------------------------------------------- -------------------------------------------------------------------------------------- ----------------------------------------------------------------- ------- --------- ---------- --------- ---------- ----------- --------- ---------- ---------- ---------
  E~2~                                        1.9                                                                                    1.7                                                               1.1     100.0     100.0      1.0       100.0      100.0       1.0       100.0      100.0      1.0
  NDC-1022                                    495.0                                                                                  80.0                                                              6.2     4.9       89.0       18.1      24.7       96.3        3.9       88.1       95.5       1.1
  NDC-1308[c](#tblfn7){ref-type="table-fn"}   70.0                                                                                   100.0                                                             0.7     4.7±0.3   28.1±8.8   6.0±1.5   14.3±0.3   60.7±11.3   4.2±0.7   68.5±5.7   84.6±9.5   1.2±0.5
  NDC-1352                                    2250.0                                                                                 21.0                                                              107.1   3.3       61.8       18.6      4.3        92.3        21.5      7.0        130.7      18.7

Functional selectivity values are determined as the percentage of the E~2~ maximum transcriptional response (100%) for 10 nM, *n*=3.

The ligand-binding affinity was measured in a competitive assay using recombinant ERs incubated with ^3^H-E~2~ in the presence or absence of E~2~ analogs.

The functional selectivity of NDC-1308 was measured in two trials; presented is the mean±[s.e.m]{.smallcaps}.

###### 

Potency of the E~2~ analogs to kill human tumor cell lines

  **Tumor type**              **Cell line**   **Tamoxifen**   **E~2~**   **NDC-1022**   **NDC-1308**   **NDC-1352**                                                                                                         
  --------------------------- --------------- --------------- ---------- -------------- -------------- -------------- --------- ---------- ------------ --------- ---------- ---------- --------- ------------ ------------ ---------
  Colon                       HT-29           4.9             8.4        1.7            ND             ND             ND        65.4       102.7        1.6       18.4       27.5       1.5       76.2         133.6        1.8
  Prostate                    PC-3            11.2            31         2.8            ND             ND             ND        59.7       145.2        2.4       15.3       31.9       2.1       137.5        361.7        2.6
  Breast                      MCF-7           10.3            32.2       3.1            22.5           53.5           2.4       30.3       114.7        3.8       6.9        29.1       4.2       63.9         263.3        4.1
                              MDA-MB-231      11.9            33.4       2.8            35.8           40.1           1.1       39.1       318.1        8.1       12.0       36.4       3.0       73.6         413.6        5.6
  Lung                        A-549           13.9            26.1       1.9            25.8           56.1           2.2       53.0       177.9        3.4       13.6       32.1       2.4       150.7        576.8        3.8
                              NCI-H23         13.3            18.3       1.4            34.1           78.5           2.3       59.3       213.2        3.6       15.3       30.2       2.0       119.2        461.6        3.9
  Ovary                       SK-OV-3         8.4             17.4       2.1            18.1           56.8           3.1       63.7       176.4        2.8       13.9       30.7       2.2       106.0        332.3        3.1
                              OVCAR-3         18.5            42.9       2.3            27.6           76.1           2.8       85.5       340.1        4.0       31.0       87.7       2.8       143.1        844.8        5.9
  Pancreas                    CAPAN-2         14.4            25.8       1.8            45.5           149.5          3.3       47.8       211.4        4.4       20.7       45.4       2.2       133.1        640.7        4.8
                              CAPAN-1         17.5            28.4       1.6            52.5           213.0          4.1       33.0       102.1        3.1       13.5       24.7       1.8       50.3         174.0        3.5
  Mean±[s.e.m.]{.smallcaps}                   14.3±1.1        26.5±2.9   1.8±0.1        32.7±3.7       90.5±18.9      3.0±0.2   57.1±5.5   203.5±24.7   3.5±0.2   18.0±2.2   41.8±7.4   2.2±0.1   117.1±11.5   505.0±74.9   4.2±0.3

The lower EC~90/50~ values help identify cell lines that are more susceptible to particular compounds.
